Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:disease
breast cancer subtype |
| gptkbp:affects |
breast tissue
|
| gptkbp:alsoKnownAs |
gptkb:IDC
|
| gptkbp:canBe |
HER2 positive
hormone receptor positive triple negative |
| gptkbp:canMetastasizeTo |
brain
lungs liver lymph nodes bones |
| gptkbp:canProgressTo |
gptkb:ductal_carcinoma_in_situ
|
| gptkbp:commonIn |
gptkb:women
|
| gptkbp:diagnosedBy |
ultrasound
biopsy mammography |
| gptkbp:firstDescribed |
19th century
|
| https://www.w3.org/2000/01/rdf-schema#label |
invasive ductal carcinoma
|
| gptkbp:ICD-10_code |
C50
|
| gptkbp:mostCommonTypeOf |
gptkb:cancer
|
| gptkbp:occurredIn |
men
|
| gptkbp:originatedIn |
ductal epithelium
|
| gptkbp:percentageOfBreastCancers |
70-80%
|
| gptkbp:prognosis |
lymph node involvement
tumor size hormone receptor status histological grade HER2 status |
| gptkbp:relatedTo |
gptkb:ductal_carcinoma_in_situ
|
| gptkbp:riskFactor |
gptkb:BRCA1_mutation
age family history alcohol consumption obesity hormone replacement therapy early menarche late menopause BRCA2 mutation |
| gptkbp:symptom |
nipple discharge
breast pain skin changes breast lump |
| gptkbp:treatment |
surgery
radiation therapy chemotherapy hormone therapy targeted therapy |
| gptkbp:bfsParent |
gptkb:triple-negative_breast_cancer
|
| gptkbp:bfsLayer |
6
|